A US jury in the District of Delaware found that Parse Biosciences, a subsidiary of Qiagen, willfully infringed three patents belonging to Scale Biosciences—acquired by 10x Genomics in 2025—while also upholding the validity of those patents. The jury awarded 10x more than $4.8 million in damages tied to Parse sales of Evercode Whole Transcriptome products. The ruling includes plans for 10x to seek enhanced damages and attorneys’ fees, and to pursue a permanent injunction to stop further infringement in the US. The lawsuit centers on patents classified as methods for identifying multiple epitopes in cells, with a fourth patent previously invalidated. The verdict raises the stakes for patent diligence in single-cell workflows and adds legal friction for multiplex immunophenotyping and barcoding method implementations.